Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

Neuro-Oncology

Volumn 11, Issue 3, 2009, Pages 281-291

  Kitange, Gaspar J ^a   Carlson, Brett L ^a   Schroeder, Mark A ^a   Grogan, Patrick T ^a   Lamont, Jeff D ^b   Decker, Paul A ^a   Wu, Wenting ^a   James, C David ^c   Sarkaria, Jann N ^a  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Glioblastoma xenografts; MGMT induction; Promoter methylation; Temozolomide

Indexed keywords

ACTIN; BETA ACTIN; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENE SILENCING; GLIOBLASTOMA; HUMAN; HUMAN CELL; LOW DRUG DOSE; METHYLATION; MGMT GENE; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; NUDE MOUSE; ONCOGENE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; TISSUE CULTURE; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOTTING, WESTERN; CELL LINE, TUMOR; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67649610349     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-090     Document Type: Article

References (45)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996. (Pubitemid 40349501)
2. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 2002;8:2725-2734. (Pubitemid 34856362)
3. Hegi M, Diserens A, Hamou M, et al. Temozolomide (TMZ) targets only glioblastoma with a silenced MGMT-gene. Results of a translational companion study to EORTC 26981/NCIC CE.3 of radiotherapy ± TMZ [abstract A-31]. Eur J Cancer. 2004;2(8 suppl 2):14.
4. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003. (Pubitemid 40349502)
5. Karran P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis. 2001;22:1931-1937. (Pubitemid 34065386)
6. Drablos F, Feyzi E, Aas PA, et al. Alkylation damage in DNA and RNA- repair mechanisms and medical significance. DNA Repair. 2004;3: 1389-1407. (Pubitemid 39221738)
7. Rasimas JJ, Dalessio PA, Ropson IJ, Pegg AE, Fried MG. Active-site alkylation destabilizes human O6-alkylguanine DNA alkyltransferase. Protein Sci. 2004;13:301-305. (Pubitemid 38021163)
8. Xu-Welliver M, Pegg AE. Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase. Carcinogenesis. 2002;23:823-830. (Pubitemid 34567522)
9. Hermisson M, Klumpp A, Wick W, et al. O-6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006;96:766-776.
10. Middlemas DS, Stewart CF, Kirstein MN, et al. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin Cancer Res. 2000;6:998-1007. (Pubitemid 30159360)
11. Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg. 2003;99:1047-1052. (Pubitemid 44717401)
12. Wedge SR, Newlands ES. O6-Benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU. Br J Cancer. 1996;73:1049-1052. (Pubitemid 26131223)
13. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-3857. (Pubitemid 29001538)
14. Hegi ME, Diserens A-C, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res. 2004;10:1871-1874. (Pubitemid 38375541)
15. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004;10:4933-4938. (Pubitemid 39099766)
16. Sarkaria JN, Carlson BL, Schroeder MA, et al. Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 2006;12:2264-2271.
17. Giannini C, Sarkaria J, Saito A, et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-Oncology. 2005;7:164-176. (Pubitemid 40590516)
18. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-797. (Pubitemid 29086728)
19. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354. (Pubitemid 30826035)
20. Hirose Y, Kreklau EL, Erickson LC, Berger MS, Pieper RO. Delayed repletion of O6-methylguanine-DNA methyltransferase resulting in failure to protect the human glioblastoma cell line SF767 from temozolomide-induced cytotoxicity. J Neurosurg. 2003;98:591-598. (Pubitemid 36262781)
21. Kaina B, Muhlhausen U, Piee-Staffa A, et al. Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J Pharmacol Exp Ther. 2004;311:585-593. (Pubitemid 39391543)
22. Barvaux VA, Lorigan P, Ranson M, et al. Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine- DNA alkyltransferase. Mol Cancer Ther. 2004;3:1215-1220. (Pubitemid 39440166)
23. Reese JS, Davis BM, Liu L, Gerson SL. Simultaneous protection of G156A methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and sensitization of tumor cells using O6-benzylguanine and temozolomide. Clin Cancer Res. 1999;5:163-169. (Pubitemid 29045190)
24. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, Gerson SL. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res. 2001;7:2309-2317. (Pubitemid 32751629)
25. Middleton MR, Lee SM, Arance A, Wood M, Thatcher N, Margison GP. O6-methylguanine formation, repair protein depletion and clinical outcome with a 4-hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer. 2000;88:469-473. (Pubitemid 30747071)
26. Kato Y, Okollie B, Raman V, et al. Contributing factors of temozolomide resistance in MCF-7 tumor xenograft models. Cancer Biol Ther. 2007;6:891-897. (Pubitemid 351574979)
27. Frosina G, Laval F. The O6-methylguanine-DNA-methyltransferase activity of rat hepatoma cells is increased after a single exposure to alkylating agents. Carcinogenesis. 1987;8:91-95. (Pubitemid 17130655)
28. Laval F. Increase of O6-methylguanine-DNA-methyltransferase and N3-methyladenine glycosylase RNA transcripts in rat hepatoma cells treated with DNA-damaging agents. Biochem Biophys Res Commun. 1991;176:1086-1092.
29. Habraken Y, Laval F. enhancement of 1,3-bis(2-chloroethyl)-1- nitrosourea resistance by gamma-irradiation or drug pretreatment in rat hepatoma cells. Cancer Res. 1991;51:1217-1220.
30. Fritz G, Kaina B. Stress factors affecting expression of O6-methylguanine- DNA methyltransferase mRNA in rat hepatoma cells. Biochim Biophys Acta. 1992;1171:35-40.
31. Chan CL, Wu Z, Eastman A, Bresnick E. Irradiation-induced expression of O6-methylguanine-DNA methyltransferase in mammalian cells. Cancer Res. 1992;52:1804-1809.
32. Chan CL, Wu Z, Eastman A, Bresnick E. Induction and purification of O6-methylguanine-DNA-methyltransferase from rat liver. Carcinogenesis. 1990;11:1217-1221. (Pubitemid 20236287)
33. Lefebvre P, Zak P, Laval F. Induction of O6-methylguanine-DNA- methyltransferase and N3-methyladenine-DNA-glycosylase in human cells exposed to DNA-damaging agents. DNA Cell Biol. 1993;12:233-241. (Pubitemid 23121005)
34. Grombacher T, Mitra S, Kaina B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis. 1996;17:2329-2336. (Pubitemid 26402229)
35. Fritz G, Tano K, Mitra S, Kaina B. Inducibility of the DNA repair gene encoding O6-methylguanine-DNA methyltransferase in mammalian cells by DNA-damaging treatments. Mol Cell Biol. 1991;11:4660-4668. (Pubitemid 21895863)
36. Grombacher T, Eichhorn U, Kaina B. P53 is involved in regulation of the DNA repair gene O-6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents. Oncogene. 1998;17:845-851. (Pubitemid 28430207)
37. Wilson RE, Hoey B, Margison GP. Ionizing radiation induces O6- alkylguanine-DNA-alkyltransferase mRNA and activity in mouse tissues. Carcinogenesis. 1993;14:679-683. (Pubitemid 23150002)
38. Schmerold I, Wiestler OD. Induction of rat liver O6-alkylguanine- DNA alkyltransferase following whole body X-irradiation. Cancer Res. 1986;46:245-249. (Pubitemid 16189059)
39. Schmerold I, Spath A. Induction of rat liver O6-alkylguanine-DNA alkyltransferase by bleomycin. Chem Biol Interact. 1986;60:297-304. (Pubitemid 17212873)
40. Bhakat KK, Mitra S. CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis. 2003;24:1337-1345. (Pubitemid 37038823)
41. Biswas T, Ramana CV, Srinivasan G, et al. Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene. 1999;18:525-532. (Pubitemid 29060628)
42. Nakagawachi T, Soejima H, Urano T, et al. Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine- DNA methyltransferase (MGMT) gene expression in human cancer. Oncogene. 2003;22:8835-8844. (Pubitemid 38021499)
43. Sato K, Kitajima Y, Nakagawachi T, et al. Cisplatin represses transcriptional activity from the minimal promoter of the O6-methylguanine methyltransferase gene and increases sensitivity of human gallbladder cancer cells to 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-2- chloroethyl)-3- nitrosourea. Oncol Rep. 2005;13:899-906.
44. Costello JF, Futscher BW, Tano K, Graunke DM, Pieper RO. Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem. 1994;269:17228-17237. (Pubitemid 24204047)
45. Pieper RO, Costello JF, Kroes RA, et al. Direct correlation between methylation status and expression of the human O-6-methylguanine DNA methyltransferase gene. Cancer Commun. 1991;3:241-253.